Int. J. Mol. Sci. 2013, 14(4), 7341-7355; doi:10.3390/ijms14047341
Article

Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes

1 Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg, Ulmenweg 18, Erlangen 91054, Germany 2 Department of Otorhinolaryngology, Head and Neck Surgery, Section for Experimental Oncology and Nanomedicine (SEON), University Hospital Erlangen, Waldstrasse 1, Erlangen 91054, Germany These authors contributed equally to this work. These authors contributed equally to senior authorship.
* Author to whom correspondence should be addressed.
Received: 3 December 2012; in revised form: 8 March 2013 / Accepted: 8 March 2013 / Published: 2 April 2013
(This article belongs to the Special Issue Bioactive Nanoparticles 2012)
PDF Full-text Download PDF Full-Text [1858 KB, uploaded 2 April 2013 10:24 CEST]
Abstract: Magnetic drug targeting (MDT) improves the integrity of healthy tissues and cells during treatment with cytotoxic drugs. An anticancer drug is bound to superparamagnetic iron oxide nanoparticles (SPION), injected into the vascular supply of the tumor and directed into the tumor by means of an external magnetic field. In this study, we investigated the impact of SPION, mitoxantrone (MTO) and SPIONMTO on cell viability in vitro and the nonspecific uptake of MTO into circulating leukocytes in vivo. MDT was compared with conventional chemotherapy. MTO uptake and the impact on cell viability were assessed by flow cytometry in a Jurkat cell culture. In order to analyze MTO loading of circulating leukocytes in vivo, we treated tumor-bearing rabbits with MDT and conventional chemotherapy. In vitro experiments showed a dose-dependent MTO uptake and reduction in the viability and proliferation of Jurkat cells. MTO and SPIONMTO showed similar cytotoxic activity. Non-loaded SPION did not have any effect on cell viability in the concentrations tested. Compared with systemic administration in vivo, MDT employing SPIONMTO significantly decreased the chemotherapeutic load in circulating leukocytes. We demonstrated that MDT spares the immune system in comparison with conventional chemotherapy.
Keywords: chemotherapy; iron oxide nanoparticles; mitoxantrone; magnetic drug targeting; immune system; leukocytes

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Janko, C.; Dürr, S.; Munoz, L.E.; Lyer, S.; Chaurio, R.; Tietze, R.; Löhneysen, S.V.; Schorn, C.; Herrmann, M.; Alexiou, C. Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes. Int. J. Mol. Sci. 2013, 14, 7341-7355.

AMA Style

Janko C, Dürr S, Munoz LE, Lyer S, Chaurio R, Tietze R, Löhneysen SV, Schorn C, Herrmann M, Alexiou C. Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes. International Journal of Molecular Sciences. 2013; 14(4):7341-7355.

Chicago/Turabian Style

Janko, Christina; Dürr, Stephan; Munoz, Luis E.; Lyer, Stefan; Chaurio, Ricardo; Tietze, Rainer; Löhneysen, Sarah V.; Schorn, Christine; Herrmann, Martin; Alexiou, Christoph. 2013. "Magnetic Drug Targeting Reduces the Chemotherapeutic Burden on Circulating Leukocytes." Int. J. Mol. Sci. 14, no. 4: 7341-7355.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert